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Introduction
The glomerulus of the kidney is a specialized capillary bed that 
generates an ultrafiltrate that, after modification by the kidney 
tubule system, becomes urine. Diseases of the glomerulus often 
lead to chronic kidney disease, a major health care problem affect-
ing between 5% and 10% of the adult population in developed 
countries (1). Treatment options are limited, in part owing to the 
poor understanding of the pathogenesis of glomerular disease. 
Better insights into the root cause of this disease will offer hope 
for improvement of this situation.
One of the most common glomerular syndromes is focal seg-
mental glomerulosclerosis (FSGS). The pathologic change of FSGS 
is a scar that develops focally (in some but not all glomeruli) and seg-
mentally (in only part of a glomerulus). While originally considered 
a disease, FSGS is now thought to consist of a variety of different syn-
dromes. These include primary (idiopathic) FSGS, which is thought 
to be caused by a circulating factor, and secondary FSGS, which may 
be caused by viruses, medications, and genetic mutations. The most 
common form of secondary FSGS follows glomerular hyperfiltration 
arising from a mismatch between metabolic load and glomerular 
capacity and is associated with obesity, low birth weight, reduced 
renal mass, and other causes. Genetic mutations alone can be suffi-
cient to cause disease (Mendelian) or may increase susceptibility to 
FSGS by potentiating the effects of environmental factors.
The glomerulus is composed of 3 different cell types: endo-
thelial cells, mesangial cells, and epithelial cells known as podo-
cytes. The podocyte is an unusual cell that covers the outside of 
the capillary wall and interdigitates with other podocytes to create 
small slits that allow the passage of fluid and small solutes into the 
urinary space. It is now clear that podocyte dysfunction is respon-
sible for FSGS as well as other glomerular diseases such as min-
imal change disease, membranous glomerulopathy, and congen-
ital nephrotic syndrome. Current models suggest that increased 
podocyte loss is the primary lesion in FSGS (2–5).
Over the past 10 years, various genetic approaches have iden-
tified mutations in over 20 podocyte genes as causative or leading 
to increased susceptibility to FSGS (6, 7). Mutations in these genes, 
however, explain only a small fraction of familial and sporadic 
FSGS cases (8–10). A larger fraction of cases may involve non- 
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should be broadly applicable to studying other uncommon dis-
eases in which susceptibility genes are suspected.
Results
Sequencing of DNA from FSGS patients. We conducted high-through-
put DNA-sequencing studies focusing on 2,500 genes (~7 Mb) 
(Supplemental Table 1; supplemental material available online 
with this article; doi:10.1172/JCI82592DS1) that are highly 
expressed in podocytes, reasoning that the genetic susceptibility 
would be intrinsic to the podocyte (Supplemental Figure 1A). The 
list of genes that we sequenced included most genes currently 
implicated in familial FSGS (13, 19–23), approximately 200 genes 
that are functionally linked to these genes, 677 genes chosen on 
the basis of their high expression in microdissected human glom-
eruli (24), and 1,600 human orthologs of highly expressed genes 
identified by DNA microarrays of mouse podocytes (25–27).
We performed sequencing of DNA from 214 patients of 
European ancestry with biopsy-confirmed FSGS, including 192 
patients with sporadic FSGS and 22 with familial FSGS. DNA sam-
ples were obtained from patients participating in a multicenter 
NIH study of biopsy-confirmed FSGS (16) and from patients diag-
nosed at Washington University. All subjects provided informed 
consent for the genetic studies. We focused on patients of Euro-
pean ancestry, because a well-characterized control set used for a 
genetic study of autism but unascertained for kidney disease was 
available that had a similar genetic ancestry (28). A similar control 
dataset for African or African admixture patients was not available 
at the time we performed this sequencing study, which prevented 
us from including these patients in our analysis.
To validate that our patient sequencing data were comparable 
to those of our control group, we processed data for both patients 
and controls in a single batch, with raw data aligned to the human 
genome (29–31). The depth of coverage was compared between 
patients and controls, and only those exons covered adequately 
(>20 times) and similarly in both patients and controls were 
advanced to the analysis stage (Supplemental Figure 1B). In sum-
mary, 16,784 exons and 2,769,942 bp were confidently covered 
in both patient and control cohorts, resulting in 16,008 SNPs and 
1,724 genes analyzed in the final dataset. SNP calls were equally 
represented in patients and controls.
Thirty-two patients were removed from the study but reserved 
for follow-up because trace Hispanic ancestry was detected by 
principal component analysis (PCA) (Figure 1, A–C). Three patients 
were removed because the call rate of SNPs was less than 95%. The 
remaining FSGS patients (157 sporadic and 22 familial) had a sim-
ilar number of SNPs, heterozygous genotypes, and genotypes con-
taining an alternative allele per sample (Figure 1, E–G), allowing us 
to proceed to association analysis. Our final dataset contained 179 
patients and 378 controls and included 157 sporadic and 22 famil-
ial FSGS patients. The accuracy of our analysis strategy was con-
firmed by resequencing key SNPs using Sanger sequencing and by 
showing that sequencing the same sample at both the Broad Insti-
tute and Washington University gave similar results.
No susceptibility genes were identified by single-variant analysis. 
An association test examining single variants (minor allele fre-
quency [MAF] >1%) was performed using Fisher’s exact test. No 
variants were detected with a P value below the multitest threshold 
Mendelian forms of FSGS that could involve variants in multiple 
genes that interact together to generate susceptibility to podocyte 
injury and loss. Further gene discovery in oligogenic disease is 
challenged, however, by the fact that mutations will be distributed 
across many genes and be difficult to distinguish from numerous 
neutral gene variants (11, 12). A greater understanding of genetic 
causes of FSGS has the potential to elucidate molecular pathways 
that are involved in the disease.
In terms of the number of people affected, the most signifi-
cant genetic contributor to FSGS susceptibility identified to date is 
APOL1. FSGS-associated alleles of APOL1, called G1 and G2, are 
common in West African populations, likely as a consequence of 
providing resistance to trypanosomiasis (13–15). The presence of 
2 variant alleles significantly increases the risk of arterionephro-
sclerosis (hypertensive nephropathy) (odds ratio [OR] = 7), FSGS 
(OR = 17), or HIV-associated nephropathy (OR = 29) in African 
Americans (13, 16) and in South Africans (OR = 89) (17). Approxi-
mately 13% of African Americans carry 2 variant alleles and are at 
increased risk for chronic kidney disease. These variants by them-
selves largely explain the increased frequency of FSGS among 
African Americans. Despite this, the mechanisms by which APOL1 
variants cause or predispose individuals to glomerular damage 
remain unknown. As these variants are absent from individuals 
lacking any African ancestry, they are not documented to play a 
role in FSGS susceptibility in individuals of other ancestries.
Here, we used high-throughput sequencing of DNA from FSGS 
patients of Northern European ancestry to identify genes that are 
potentially involved in susceptibility to the disease. The challenge 
of studying the genetics of sporadic FSGS is the possibility that 
a large number of genes may be involved and the likelihood that 
each gene contributes only a small amount of risk for the disease. 
In addition, the relatively low incidence of FSGS in adult and pedi-
atric populations (~5/million/year) (1) and the even fewer number 
of cases that are confirmed by kidney biopsy preclude the assem-
bly of a cohort of the size required for standard genetic approaches 
like GWAS, whole-genome sequencing, or exome sequencing (18). 
Thus, most genetic studies of FSGS have been family studies.
Here, we sequenced DNA from 214 patients of European 
ancestry with biopsy-confirmed FSGS and tested a variety of 
analytic approaches to mitigate our limited sample size. Since 
FSGS is considered a disease of podocytes, we focused our 
sequencing analysis on 2,500 genes that are highly and/or spe-
cifically expressed in podocytes. This approach significantly 
reduced the multitest penalty. We also developed a robust ana-
lytic pipeline permitting the use of individuals sequenced for 
other genetic studies as controls. Since there is no in vitro assay 
for FSGS, we developed a screening method using mice. Our sys-
tem is based on a murine embryonic stem (ES) cell line with an 
FSGS-susceptible genetic background that allows for efficient, 
targeted delivery of shRNAs to generate mice that are nearly 
100% derived from the ES cells, eliminating the need for sub-
sequent breeding. This method allowed us to rapidly test 6 can-
didate genes and validate 3 new FSGS susceptibility genes. We 
expect that our system will allow for large numbers of candidate 
genes constituting the network of FSGS genes to be validated 
and that it will provide critical insight into the pathogenesis of 
this disease syndrome. In addition, our experimental approach 
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try samples that were sequenced from the Nephrotic Syndrome 
Study Network (NEPTUNE) cohort (32). This confirmed enrich-
ment of 3 of the missense sequence variants in WNK4, KANK1, and 
ARHGEF17 (Table 1). Interestingly, KANK1 was recently identified 
as a susceptibility gene for familial nephrotic syndrome (33).
Rare variant analysis identified 6 new potential FSGS suscep-
tibility genes. We analyzed the rare variants (MAF <1%) using tests 
(2 × 10–5) (Supplemental Table 2). The lack of significance is not sur-
prising, given the relatively small size of our sample. This analysis 
did confirm that the distribution of synonymous and missense vari-
ants was similar between patients and controls (Figure 1D). Table 1 
shows a list of the 10 highest-scoring variants. All the variants are 
missense variants. As a follow-up, we analyzed the 32 samples with 
Hispanic admixture, combined with 23 additional European ances-
Figure 1. Comparability of patients and controls. (A) PCA plot of FSGS patients and 1,000 genome samples. The inset shows the distribution of putative North-
ern European FSGS patients in the PCA plot in relationship to 1,000 genome samples. (B) Magnified view of the inset area in A. (C) PCA analysis of patients and 
controls is depicted as the distance from the origin. Thirty-two patients with a highly similar variant profile but with a distance of more than 0.9 were removed 
and used as a follow-up group. (D) Fisher’s exact test of the common (MAF >5%) variants showed the absence of stratification and confirmed the validity and 
quality of our method for case-control matching. (E) Comparison of the total number of variants per sample showed that patients and controls were similar. (F) 
Comparison of the total number of heterozygous genotypes showed that patients and controls were similar. (G) Comparison of the total number of heterozy-
gous and homozygous genotypes containing an alternative allele showed that patients and controls were similar. EUR, European; HISP, Hispanic; AFR, African; 
EAS, East Asian; VAR, variants; HET, heterozygous; PC1, principal component 1; PC2, principal component 2; KG, from 1000 Genomes Database.
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Our analysis of extremely rare variants (MAF <0.01%) in 
this set of 8 genes showed enrichment in 3 of these genes: GCC1, 
APOL1, and COL4A4. Examination of our follow-up group (55 sam-
ples) confirmed enrichment of a subset of the same rare variants 
found in our larger cohort in all of the genes except COL4A4 (Table 
2), supporting the findings of our rare variant analysis. Since APOL1 
and COL4A4 were already known (13–15, 37), the remainder of the 
identified genes (BPTF, DLG5, GCC1, KAT2B, WNK4, and XYLT1) 
could represent 6 new potential FSGS susceptibility genes. Notably, 
WNK4 was also identified by single-variant analysis.
Interestingly, 4 patients with sporadic FSGS carried the APOL1 
G1 variant (G1), a known risk variant for FSGS that is present in 
that compared the total numbers of rare variants between patients 
and controls. Currently, it is believed that there is an inverse cor-
relation between the frequency of the allele and the potential risk. 
Thus, at each gene, we tested 2 distinct modes of inheritance for 
FSGS: the increased presence of extremely rare alleles that are 
predicted to be highly damaging and therefore highly penetrant 
(model 1), or the presence of low-frequency and less-damaging 
alleles with risk and protective variation intermingled with neu-
tral variation (model 2). To discriminate between these 2 models, 
we analyzed 2 subsets of variants. For the first model, we used the 
Exome Aggregation Consortium (ExAC) browser (http://exac.
broadinstitute.org) to identify 5,662 missense and loss-of-func-
tion variants in our dataset that are present at a frequency of less 
than 0.01% in the European population. We then tested the bur-
den of these rare variants in FSGS patients versus controls (Sup-
plemental Table 3 and ref. 34). Using this analysis, we found that 
no genes reached a level of statistical significance for rare, highly 
penetrant variants under this model.
To examine the second model involving low-frequency risk 
and protective variants, we selected all missense and loss-of-
function variants with a MAF of less than 1% and compared their 
distribution between patients and controls using 2 different rare 
variant tests: the variable threshold (VT) (35) and the C-α test 
(36). Because the effect sizes of variants differ, the accuracy of 
each method can vary depending on the specific situation. Using 
a P value of less than 0.05 (Bonferroni-corrected P ≤ 0.00003) as 
a cutoff, no genes were identified that exceeded this value, but 8 
genes (WNK4, APOL1, DLG5, GCC1, XYLT1, KAT2B, BPTF, and 
COL4A4) had P values close to the Bonferroni-corrected value 
(P < 0.00006 to P < 0.0008, Table 2, and Supplemental Table 4). 
Since the Bonferroni test tends to be conservative and APOL1 (13–
15) and COL4A4 (37) are known FSGS genes, we selected these 
genes for further analysis as potential FSGS susceptibility genes.
Table 2. Top genes identified by rare variant analyses
C-α test Variable threshold test Allele counts
P value P value Patients Controls
XYLT1 1.74 × 10–4 1.38 × 10–3 29/178 18/378
APOL1 3.36 × 10–4 1.78 × 10–3 8/178 2/378
KAT2B 4.37 × 10–4 8.59 × 10–2 8/178 5/378
WNK4 7.63 × 10–4 3.10 × 10–4 40/178 18/378
BPTF 7.68 × 10–4 2.58 × 10–3 24/178 27/378
COL4A4 2.34 × 10–2 6.76 × 10–5 22/178 9/378
DLG5 2.96 × 10–3 7.71 × 10–5 50/178 38/378
GCC1 2.91 × 10–3 4.84 × 10–4 14/178 5/378
XYLT1 1.74 × 10–4 1.38 × 10–3 29/178 18/378
Rare, missense, and nonsense variants (MAF <1%) were pooled for rare 
variant analysis using variable threshold and C-α tests. The top genes 
identified by each test are shown ranked by P value. Genes with P values 
of less than 8 × 10–4 were selected for further analysis. P values were 
determined by the rare variant gene association tests C-α and VT. The 
complete list of gene association results is shown in Supplemental Table 4.
Table 1. Single variants enriched in patients versus controls and in the follow-up cohort
Patients versus controls Follow-up
CHROM.POS GENE_NAME REF ALT MAF MINA SMINA FMINA MINU ESP_EA ESP_AA P value FLW_ALT FLW_AF
chr17:40947320 WNK4 C T 5.4 × 10–3 6 6 0 0 1.3 × 10–3 4.95 × 10–1 1.0 × 10–3 2 1.8 × 10–2
chr9:710966 KANK1 G A 2.1 × 10–2 15 15 0 8 8.0 × 10–3 4.95 × 10–1 1.1 × 10–3 14 1.3 × 10–1
chr2:113737630 IL36G C A 4.8 × 10–3 5 5 0 0 1.0 × 10–3 1.23 × 10–1 1.5 × 10–3 0 0
chr11:73020633 ARHGEF17 G C 4.5 × 10–3 5 5 0 0 2.0 × 10–3 2.53 × 10–1 2.8 × 10–3 9 8.2 × 10–2
chr17:40939855 WNK4 G T 4.5 × 10–3 5 5 0 0 1.2 × 10–3 2.07 × 10–1 3.2 × 10–3 2 1.8 × 10–2
chr22:36661906 APOL1 A G 4.5 × 10–3 5 5 0 0 3.4 × 10–4 2.26 × 10–1 3.2 × 10–3 7 6.4 × 10–1
chr17:40947320 KANK1 G A 2.1 × 10–2 15 15 0 8 8.0 × 10–3 4.95 × 10–1 1.1 × 10–3 2 1.8 × 10–2
chr9:710966 IL36G C A 4.8 × 10–3 5 5 0 0 1.0 × 10–3 1.23 × 10–1 1.5 × 10–3 14 1.3 × 10–1
chr2:113737630 ARHGEF17 G C 4.5 × 10–3 5 5 0 0 2.0 × 10–3 2.53 × 10–1 2.8 × 10–3 0 0
chr11:73020633 WNK4 G T 4.5 × 10–3 5 5 0 0 1.2 × 10–3 2.07 × 10–1 3.2 × 10–3 9 8.2 × 10–2
chr17:40939855 APOL1 A G 4.5 × 10–3 5 5 0 0 3.4 × 10–4 2.26 × 10–1 3.2 × 10–3 2 1.8 × 10–2
CHROM.POS, chromosome position of the variant; REF, reference allele; ALT, alternative allele (variant); MINA, number of alternative alleles in patients; 
MINU, number of alternative alleles in controls; SMINA, number of alternative alleles in patients with sporadic FSGS; FMINA, number of alternative alleles 
in patients with familial FSGS; ESP_EA, allele frequency in European Americans in the NHLBI Exome Sequencing Project; ESP_AA, allele frequency in 
African Americans in the NHLBI Exome Sequencing Project; FLW_ALT, number of alternative alleles in the follow-up cohort; FLW_AF, allele frequency in the 
follow-up cohort. The frequency of single variants (MAF >1%) was assessed in patients versus controls, and high-scoring variants with ORs greater than 2.5 
are shown in this table ranked by P value (P values were determined by Fisher’s exact test). For each variant, the number of patients and frequency in the 
follow-up cohort are shown on the right.
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25 have a variant in one of the known 
disease genes (38). There was also 
a difference in the total number of 
unique rare variants identified in 
patients (32.9%, 59 variants in 179 
patients) versus controls (3.9%, 15 
variants in 378 control subjects) (Sup-
plemental Table 7). The significance 
of this finding was tested using a 
permutation analysis of differences 
in variants between patients and con-
trols in all potential random groups of 
20 genes chosen from our database 
of 1,724 genes. This showed, how-
ever, that 27% of the random sets of 
20 genes had a similar or higher bur-
den of rare variants compared with 
the set of 20 FSGS genes. This sug-
gests that our patient dataset contains 
additional novel FSGS susceptibility 
genes with strong genetic effects.
Development of a high-throughput 
method to validate candidate genes in 
mice. Since FSGS cannot be modeled 
in vitro and most confirmatory stud-
ies are performed today in zebrafish 
(33, 39–41), we developed a genetic 
system in mice to examine the func-
tion of candidate genes in vivo. Our 
strategy involved inhibiting the 
expression of candidate genes in 
podocytes from mice on a genetic 
background that is prone to develop 
FSGS. Mice that are heterozygous 
for 2 podocyte genes, Cd2ap and 
Synpo, develop FSGS with an incom-
plete penetrance (~25%–50%) and 
significant albuminuria occurring at 
about 6 months of age (42). Assuming that FSGS is an oligogenic 
disease, we reasoned that knocking down a bona fide disease gene 
in this background would accelerate disease onset.
We generated a mouse ES cell line that was Cd2ap+/– and 
Synpo+/– using standard methods. The ES cell also expresses a podo-
cyte-specific and doxycycline-inducible (DOX-inducible) trans-
activator (Nphs1-rtTA3G) that allows inducible expression of an 
shRNA (Figure 2A and ref. 43). We reasoned that inducible RNAi 
would allow us to study the role of a gene in the mature kidney with-
out worrying about developmental effects. The new method using 
laser-assisted microinjection into 8-cell embryos (44) allowed us 
to generate mice that were nearly 100% derived from the ES cells 
without further breeding (Figure 2B). Consistent with mice gen-
erated by conventional breeding, approximately 50% of the mice 
generated from these ES cells developed mild proteinuria after 12 
to 16 weeks of age (Figure 2C). To eliminate variability introduced 
by random integration of an RNAi transgene, we targeted a single 
copy of the RNAi transgene into the mouse Hprt1 locus (45) that 
allows the use of 6-thioguanine for efficient selection (Figure 3A).
29% of African Americans but is a rare variant (0.03%) in European 
Americans. This finding was also seen in the follow-up set, in which 
7 of 55 additional samples were identified with this mutation. Since 
the allele frequency of the APOL1 G1 allele in approximately 5,500 
Hispanic samples in the ExAC dataset was only 0.5%, this represents 
significant enrichment, regardless of the Hispanic admixture.
Testing for the enrichment of rare variants in 20 previously known 
FSGS genes. Family studies have identified nearly 30 genes that 
cause familial FSGS (6). To determine whether a set of 20 of these 
genes (Supplemental Table 5) are also involved in sporadic FSGS, 
we assessed the frequencies of predicted damaging, rare coding 
variants (missense and loss-of-function with a MAF <1%) in these 
genes in patients and controls. Approximately 36.9% of patients (66 
of 179) had at least 1 predicted deleterious rare variant in these 20 
genes compared with 3.4% of controls (13 of 378) (the list of variants 
is shown in Supplemental Tables 6 and 7). The distribution of vari-
ants between familial and sporadic cases was similar and consistent 
with previous studies showing that approximately 30% of steroid- 
resistant nephrotic syndrome patients presenting before the age of 
Figure 2. Development of ES cells sensitized for FSGS. (A) Identification of FSGS-sensitized ES cells. Our 
breeding strategy predicted that 1 of 8 embryos would have the correct genotype. ES cells were generated 
using standard approaches and genotyped for Cd2ap heterozygosity (upper panel), the NEFTA transgene 
(middle panel), and the Y chromosome (lower panel). (B) Laser-assisted injection generated mice with high 
chimerism. In the example shown, the ES cell line (agouti) was injected into 8-cell C57/BL6 (black) embryos. 
Compared with noninjected embryos (resulting in the 2 black mice shown on the bottom), all of the injected 
embryos generated pups that were close to being purely agouti. Injection of ES cells into C57/BL6 albino 
embryos resulted in completely agouti animals (not shown). (C) Mice generated from ES cells developed mild 
proteinuria after 4 months, with no DOX treatment. Fifteen mice were generated from the sensitized ES cells 
and treated with or without DOX in the drinking water. Urine was tested every month by measuring the albu-
min/creatinine ratios. Mice developed low-level proteinuria at 4 months of age, but the level of proteinuria 
was not affected by DOX treatment.
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Since Cd2ap is an FSGS disease gene (46) and knockout 
(KO) mice develop severe proteinuria (47), we validated our sys-
tem by generating Cd2ap RNAi mice. Multiple Cd2ap-specific 
RNAis were tested for their ability to inhibit Cd2ap expression 
(Figure 3B and Supplemental Figure 2A), and the RNAi show-
ing the greatest inhibition (sh877) was embedded into a miR30 
sequence that allows for DOX-inducible expression (Supple-
mental Figure 2, B and C, and ref. 48). An RNAi for the firefly 
luciferase gene (FF3) was used as a control. Half of the founder 
(F0) animals were treated with DOX at 2 weeks of age to induce 
shRNA transgene expression. All of the DOX-treated mice 
developed sustained proteinuria that was over 150-fold higher 
than that seen in the control animals (Figure 3C). Histological 
analysis of the kidneys revealed protein casts in the tubules 
(Figure 3D). Electron microscopic examination of the kidney 
showed widespread foot process effacement, a marker of pro-
teinuria (Figure 3E), validating that our RNAi strategy could be 
used to test candidate FSGS genes. Interestingly, the proteinuric 
mice recovered after removal of DOX treatment (Supplemental 
Figure 2D). In contrast, FF3-RNAi mice did not show proteinuria 
after treatment with DOX for 8 weeks (Figure 3F), and no abnor-
malities were detected by electron microscopy or histology 
(Supplemental Figure 2E).
Validation of WNK4, KANK1, and ARHGEF17 as potential FSGS 
susceptibility genes. Three of the six genes, WNK4, DLG5, and 
KAT2B, identified by rare variant analysis were chosen for testing. 
We also chose the 3 single-variant candidates, KANK1, WNK4, 
and ARHGEF17. Since WNK4 was present on both lists, a total 
of 5 genes were selected for analysis. Because the exact mouse 
ortholog for human KANK1 is unknown, because Kank2 is more 
highly expressed in mouse podocytes (49), and because Kank1 
and Kank2 were recently identified as susceptibility genes for 
nephrotic syndrome, we targeted both Kank1 and Kank2. Multiple 
shRNAs were generated for the 6 candidate genes. Their efficacy 
was validated in vitro, and the best one was targeted to the Hprt1 
locus (Figure 4A and Supplemental Figure 3, A and B). Two inde-
pendent clones for each candidate gene were selected, and 15–30 
mice were generated by laser-assisted microinjection.
Half of each cohort was given DOX, and proteinuria (albu-
min/creatinine), an indicator of podocyte function, was assessed 
at 4 and 8 weeks after DOX treatment (Figure 4, B–G). All 3 RNAi 
transgenes, Wnk4, Arhgef17, and Kank2, induced substantial pro-
teinuria, with a level of proteinuria that was significantly higher 
than that seen in the control mice (Figure 4, B–E). In contrast, the 
Dlg5, Kat2b, and Kank1 RNAi mice did not show statistically signifi-
cant elevations of proteinuria after 4 or 8 weeks of DOX treatment. 
Figure 3. Validation of the system using 
CD2AP knockdown. (A) Targeting strategy 
used to integrate a miR30-shRNA trans-
gene into the Hprt1 locus. (B) Knockdown 
efficiency of a miR30-shRNA for Cd2ap 
(sh877). Immunoblot shows endogenous 
CD2AP in NIH3T3 cells stably transduced 
with FF3 (control shRNA) or sh877. The 
validation of sh877 is shown in Supplemen-
tal Figure 2A. Panel B represents multiple 
experiments (n = 3) conducted to test the 
efficiency of the RNAi. (C) Sixteen mice 
generated with ES cells with the Cd2ap 
shRNA that was targeted to the Hprt1 locus 
were treated with or without DOX, and 
urine was analyzed by measuring the urine 
albumin/creatinine ratio at 4 and 8 weeks. 
(D) Histology from a representative Cd2ap 
RNAi mouse treated with DOX showing 
protein casts (indicated with asterisks;  
n >5). (E) Representative electron micro-
scopic image from a Cd2ap RNAi mouse 
treated with DOX shows podocyte foot 
process (FP) effacement. En, endothelial 
cells (n = 9). (F) Thirteen control mice were 
generated with a control luciferase RNAi 
targeted to the Hgprt locus. Mice were 
treated with (n = 6) or without (n = 7) DOX, 
and urine was analyzed by measuring the 
albumin/creatinine ratio at 4 and 8 weeks. 
A 2-tailed Mann-Whitney U test was used 
to calculate the P values in C and F. A P 
value of less than 0.05 was considered 
statistically significant.
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Figure 4. Validation of 5 candidate FSGS disease genes. (A) Validation of shRNAs for Arhgef17, Dlg5, Kank1, Kank2, Wnk4, and Kat2b. As described in 
Methods, shRNAs were tested for the ability to inhibit a target sequence fused to GFP in 293 cells. GFP immunoblotting was used to measure the degree 
of inhibition. Each immunoblot is representative of at least 3 independent experiments measuring RNAi efficiency. (B–G) Mouse validation screening 
for candidate FSGS genes. ES cells were generated with the specific RNAis targeted to the Hgprt locus. Essentially pure chimeric mice were generated by 
laser-assisted microinjection of ES cells into C57BL6 8-cell embryos. Injections generally resulted in cohorts of 14 to 30 animals; smaller cohorts of animals 
were not used. Mice were divided into 2 groups and treated with or without DOX to induce expression of the RNAi transgene. Urine albumin/creatinine 
ratios were measured 4 and 8 weeks after DOX treatment. Albumin/creatinine ratios are shown for each cohort of mice at the indicated time points. A 
2-tailed Mann-Whitney U test was used to calculate the P values for B–G. A P value of less than 0.0083 was considered statistically significant (multitest 
penalty was used).
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are thought to enhance the rate of podocyte loss, and this increases 
the probability of developing FSGS. Interpreted this way, the FSGS 
“lesion” likely represents the common outcome of a wide variety 
of pathogenetic causes.
In validating genetic susceptibility in sporadic FSGS, a signifi-
cant challenge is the likelihood that a large number of genes may 
be involved and that each gene contributes only a small amount of 
risk for the disease. Additionally, the role of mutations in a specific 
gene may affect only a small number of patients. This substan-
tially increases the challenge of gene identification in any large 
genetic study. An additional complication is that sporadic FSGS 
is relatively uncommon, and most patients do not have a biopsy-
confirmed diagnosis. This currently precludes the assembly of a 
large enough cohort for strong statistical analysis. Because of this, 
most of the FSGS disease genes identified to date are from fam-
ily studies, from the sequencing of candidate genes based on the 
phenotype of mouse models, or from admixture linkage studies of 
African Americans (13, 19–23, 25, 46, 53–56).
Here, we used next-generation sequencing to identify FSGS 
susceptibility genes. Because of our relatively modest sample 
size, we adjusted our analytic approach to maximize our ability to 
identify candidate genes. As both rare and common variants have 
allele frequencies that are determined by ancestry, well-matched 
controls for ancestry are required. Since large control datasets 
for individuals of European ancestry are already available, we 
focused on FSGS subjects of European ancestry. Because DNA 
variant calling can be different between institutions and between 
platforms, we established a pipeline to validate that the datasets 
were comparable. FSGS is more common in African Americans, 
but the complex genetic admixture in this population will require 
a large and complex control dataset that is currently not available. 
Our focus on genes expressed in podocytes allowed us to focus on 
higher-likelihood genes and minimized the multitest penalty.
Genetic analysis of FSGS is challenging because of the poten-
tially broad genetic heterogeneity of the disease and the relatively 
small number of subjects available for analysis when the subjects’ 
ancestry needs to be controlled. Rare variant analysis in ethnically 
admixed populations such as those found in the United States will 
require new statistical approaches and the development of large, 
ancestrally matched control datasets. Nonetheless, our work 
shows that current statistical approaches, combined with focused 
sequence analysis, can identify candidate genes from a relatively 
small sample for a syndrome like FSGS that has widely divergent 
etiologies. While our sample size was sufficient to extract a list of 
candidate genes using rare variant analysis, a sample size of at 
least one order of magnitude larger would be necessary to gen-
erate statistically significant data for the single variants (18). Our 
sample size, however, allowed for a candidate susceptibility list 
to be generated from both rare and single variants that we were 
able to confirm using a small confirmatory or follow-up dataset. 
Although large-scale whole-exome and whole-genome–sequenc-
ing efforts are becoming more commonplace, focused approaches 
on subsets of genes may have biological and statistical advantages 
in diseases for which samples are limited.
True validation of some of these genes in humans will prob-
ably require identification of high-penetrant familial mutations 
in some of these genes and/or analysis of a much larger group of 
Because there was a slight trend toward increased proteinuria in 
the Kat2b and Kank1 mice, we followed the proteinuria levels for 
an additional 4 weeks. After 12 weeks, Kank1 mice had a clear pro-
teinuric phenotype, while the proteinuria present in Kat2b mice 
was still not significant (Supplemental Figure 4A). Thus, Wnk4, 
Arhgef17, Kank1, and Kank2 mice were positive for proteinuria, 
while Dlg5 and Kat2b mice were negative for proteinuria.
We confirmed the Dlg5 result by obtaining Dlg5-KO mice 
(50) and generating Dlg5, Cd2ap, and Synpo triple-heterozygous 
mice using conventional breeding. No kidney dysfunction was 
detected (Supplemental Figure 4B), confirming our RNAi result. 
As expected, electron microscopic examination of the kidneys 
showed podocyte foot process effacement in Arhgef17, Kank1 (12 
week-time point), Kank2, and Wnk4 mice, but not in Dlg5 RNAi 
mice (Supplemental Figure 4A). While the overall morphology 
was normal, some focal areas of mild foot process effacement 
could be seen in the Kat2b mice.
Testing for the enrichment of rare variants in patients versus controls 
in 20 previously known FSGS genes plus 3 new genes. We added KANK1, 
WNK4, and ARHGEF17 to the list of the 20 known FSGS genes and 
reanalyzed differences in the number of rare variants between 
patients and controls. Approximately 53.5% of patients (84 of 179) 
had at least 1 predicted deleterious rare variant in these 23 genes 
compared with 5.6% of controls (21 of 378) (Supplemental Table 7). 
We separated the patients by sporadic and familial FSGS and found 
a similar distribution, with 50% of sporadic FSGS patients and 64% 
of familial FSGS patients having variants in these 23 genes.
We tested random sets of 23 genes by permutation analysis 
of patients and controls, which showed that only 0.67% (P < 1.6 × 
10–27) of random sets of 23 genes chosen from the controls equaled or 
matched the burden of rare variants seen in the patients for these 23 
genes. This supports the idea that genetic variants in these 23 genes 
account for most of the disparity between patients and controls in 
the numbers of rare variants. This also supports the idea that a spe-
cific subset of genes may function more broadly to create a suscepti-
ble background for the development of sporadic FSGS.
Discussion
FSGS is a syndrome of diverse etiology that shares a common 
histologic pattern of focal and segmental glomerular scarring, 
together with glomerular proteinuria and progressive loss of renal 
function. The majority of FSGS cases involve primary FSGS, adap-
tive FSGS, or APOL1 FSGS; less common are viral FSGS, Mende-
lian FSGS, and medication-associated FSGS. As there are no val-
idated methods to specifically distinguish sporadic (nonfamilial) 
FSGS, the present study included subjects with both primary and 
adaptive FSGS as well as subjects with familial FSGS. Because of 
the strong predictive power of family history, and because only 
a small percentage of individuals affected by known etiological 
factors develop FSGS, the genetic background of the individual is 
thought to play an important role (7).
The critical locus of injury in FSGS is now thought to be the 
podocyte (5), a terminal-differentiated cell that has limited rep-
lication potential (51). In the normal kidney, small numbers of 
podocytes are continuously lost over time (3), and when podo-
cyte numbers drop below a critical level, kidney failure inexorably 
ensues (2, 5, 52). Environmental insults and genetic susceptibility 
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differ significantly between the sporadic and familial FSGS cases. 
A complete summary of our results is provided in Table 1.
We were surprised to identify the APOL1 G1 variant in 4 of our 
subjects and in 7 of the subjects in our follow-up set, as it is rare 
in non-African populations. The enrichment of this variant in 11 of 
208 of our non-African subjects suggests that this particular allele 
may interact with other variants, leading to susceptibility to FSGS. 
This is supported by the enrichment of rare, predicted deleterious 
APOL1 variants in our subjects. The enrichment in our European 
American subjects with variants that are common in African Amer-
icans, but rare in European Americans, was also found in WNK4, 
KANK1, and ARHGEF17. The absence of neighboring African SNPs 
suggests that these are ancestral variants and not due to admixture.
Validation method. Currently, there are few approaches to val-
idate potential susceptibility genes using animal models. While 
some important FSGS susceptibility genes have been identified and 
validated using genetic KO studies in mice (47, 57), such studies are 
labor intensive and not suitable for high-throughput screening. More 
recently, zebrafish and Drosophila are being used, given the presence 
of podocyte-like cells in these organisms and the convenience of 
knocking down gene expression (33). Differences in gene expression 
and in gene orthologs for the human gene limit the physiologic sig-
nificance of such approaches for a human disease such as FSGS.
We therefore wanted to develop an efficient mouse model that 
could be used to mimic FSGS as well as validate candidate genes. 
Since FSGS is probably oligogenic (8), we started with an FSGS 
mouse model we had generated previously that was based on 
bigenic heterozygosity of Cd2ap and Synpo. Mice with this genetic 
background develop FSGS and exhibit proteinuria with an incom-
plete penetrance (~25%) after they are over 6 months of age (42). 
Because of the slow onset of disease in only a fraction of animals, 
we reasoned that this could be a good background on which to test 
candidate FSGS genes. We generated ES cells from this background 
and confirmed that nearly pure mice generated from ES cells from 
this background developed a mild proteinuria that was first detect-
able in approximately half of our animals at around 4 months of age 
and slowly worsened after that (42). We reasoned that partial inhibi-
tion of gene expression by RNAi, combined with the heterozygosity 
of Cd2ap and Synpo, would constitute a good model of oligogenic 
FSGS. Since we did not want to confound our results with RNAi 
effects on renal development, we designed our RNAi expression 
system to be podocyte specific and inducible after birth.
We targeted shRNAs for candidate genes to the Hprt1 locus by 
homologous recombination using a strategy we have described pre-
viously (45). To achieve podocyte-specific expression, our ES cells 
also expressed a DOX-inducible transactivator molecule (rtTA3G) 
under the control of a podocyte-specific promoter (nephrin) 
(43). shRNA oligos were embedded into a miR30 transgene (48). 
Using the method of laser-assisted injection of ES cells into 8-cell 
embryos, we could generate large cohorts (10–20 mice) of almost 
identical animals in a single day of injections (44). We believe our 
study is the first to use this method to generate large numbers of 
F0 animals for genetic screening. Coat color confirmed that our 
animals were close to being completely derived from the ES cells. 
That proteinuria was only seen in some, but not all, animals prob-
ably reflects variability in the intrinsic rate of disease in our mouse 
model and the short time window we used to measure the effects.
patients. As shown by our analysis of 20 known familial variants 
in this population, their assessment individually would not have 
implicated them in the pathogenesis of disease in this population 
of subjects. However, clustering genes together allowed us to gen-
erate greater statistical power and arrive at a better understanding 
of this oligogenic disease. Given that some of our subjects had rare 
variants in more than 1 candidate gene, it is tempting to speculate 
that possessing more than 1 risk allele may increase susceptibility. 
In the future, when most, if not all, susceptibility genes are identi-
fied, a risk index could be generated on the basis of the number of 
gene variants present and their predicted deleterious effect.
Sequence analysis. An innovation of our approach was the 
development of a robust pipeline that allowed the use of data on 
individuals sequenced for other studies as controls. The ability to 
combine datasets generated at different institutions for different 
types of studies will become increasingly important and powerful 
as sequencing becomes more widespread. In our initial studies, we 
found that batch effects caused by different approaches used for 
sequencing among different institutions could be a confounding 
factor precluding the use of analyzed data generated at 2 different 
institutions. However, by applying the same sequencing read align-
ment and variant calling pipelines to the primary sequencing data 
from both patients and controls, we were able to eliminate this vari-
able. We validated our approach by establishing a method for case-
control genotype matching and removal of any stratification as well 
as verifying that primary sequencing data from 2 different institu-
tions using the same control DNA sample gave similar results.
Using a P value of less than 0.05, no genes were identified by 
rare or single-variant analysis that reached genome-wide signifi-
cance because of Bonferroni’s multiple test correction. Because 
the Bonferroni test tends to be conservative, we assembled a list 
of the top 8 genes identified by rare variant analysis and the top 3 
genes identified by single-variant analysis with P values that were 
close to the Bonferroni corrected P value. Supporting the verac-
ity of this analysis, 3 of the genes, APOL1, COL4A4, and KANK1, 
were already known FSGS susceptibility genes (13, 16, 33, 37), and 
WNK4 was identified on both lists.
We initially sequenced over 700 biopsy-confirmed FSGS sam-
ples, but most of these samples were genetically admixed, pre-
venting further analysis because of the lack of matched controls. 
We therefore focused only on the patients of European ancestry 
as defined by PCA. Because the number of patients of European 
ancestry with biopsy-confirmed FSGS is extremely small, it is 
not possible to assemble a true replication study. Also, because 
of cost, case-control studies with replication using whole-exome 
or whole-genome sequencing have, in general, been extremely 
limited and are not yet commonplace in the literature. As a con-
firmatory approach, we used the 33 samples that we had elimi-
nated because of Hispanic admixture and 23 additional European 
ancestry samples that we had sequenced subsequent to the origi-
nal analysis as a confirmatory or follow-up dataset. Our analysis 
of this second dataset confirmed an increased burden of rare vari-
ants in the 6 listed rare variants as well as an increase in 3 common 
variants (Table 1). Since WNK4 was identified by both processes 
and APOL1, COL4A4, and KANK1 are known genes, at least 7 new 
candidate genes were identified by our sequencing analysis. While 
the groups were small, the distribution of variants did not seem to 
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Subsequently, adapters for Illumina sequencing were ligated onto the 
fragments. These libraries were then hybridized to biotinylated DNA 
probes from regions of interest (manufactured by MyGenostics). After 
washing away DNA libraries that bound nonspecifically to the probes, 
DNA of interest was recovered using Dynabeads MyOne Streptavidin 
T1 (Life Technologies). Resulting DNA libraries were amplified, if 
needed, for sequencing on an Illumina HiSeq 2500.
Variant calling and data quality control. We performed alignment 
of the raw sequencing data and variant calling according to GATK best 
practices with the BWA/Picard/GATK software pipeline of the Broad 
Institute. To insure that gene loci were equally covered in both patients 
and controls, we performed quality control on patients’ and controls’ 
genotypes separately, applying the following filters: (a) retention of 
only variants that PASS all GATK quality filters; (b) retention of geno-
types with DP>10,GQ>30,AB for hets 0.3<AB<0.7, for homozygous 
alternative AB<0.3; and (c) retention of all variants with less than 5% 
missing genotypes. After applying these filters, variants were com-
bined from patients and controls, and only those variants with less 
than 5% missing genotypes in both patients and controls were kept 
for further analysis. Our final dataset contained 16,108 SNPs in 1,874 
genes. The sequencing data were deposited in the NCBI’s Sequence 
Read Archive (http://www.ncbi.nlm.nih.gov/sra/), under accession 
number SRP067711.
PCA and case-control matching. PCA was performed with Eigenstrat 
software using the common (MAF >5%) variants found in autosomes 
only. We computed a Euclidean distance from each point on the PCA 
plot to the origin and plotted distributions of this parameter for both 
patients and controls. Using the 3-sigma rule, 30 samples of mixed His-
panic ancestry were identified as outliers and removed from the dataset.
Sample statistics and case-control–matching metrics were com-
puted using PLINK/SEQ analysis software. We used the number of 
variants called per sample, the number of heterozygous genotypes 
per sample, and the number of genotypes with minor allele per sam-
ple as a metric representing the genetic background of the cohort. 
The similarity between the genetic background of patients and con-
trols was established by matching the mean and variance of patient 
and control distributions for every metric. We tested the validity of 
this approach by running Fisher’s exact test on the common variation 
and QQ-plot of the P values. This showed no inflation, confirming the 
absence of any population stratification in the case-control dataset 
(Supplemental Figure 1).
Mouse strains. Cd2ap+/– mice were generated previously (47). 
Synpo–/– mice were obtained from Peter Mundel’s laboratory (60). The 
Nphs1-rtTA3G (NEFTA) strain was a gift from Jeffrey Miner’s laboratory 
(43).The Dlg5+/– mouse strain was a gift from Valeri Vasioukhin’s labo-
ratory (50). All mouse strains were genotyped by established methods.
Generation of a male Cd2ap+/–, Synpo+/–, NEFTA+ ES cell line. To 
generate a male ES cell line that was sensitized to FSGS, we bred 
Cd2ap+/– Synpo–/– males with NEFTA+ females. The females were 
superovulated using standard methods. After mating, the embryos 
were isolated at the 8-cell stage (morulae) and cultured overnight 
in EmbryoMax KSOM medium (MR-121-D; EMD Millipore) micro-
drops overlaid with mineral oil at 5% CO2 and 37°C. Blastocysts were 
transferred, 1 per well, into 48-well plates with γ-irradiated mouse 
embryonic fibroblast (MEF) feeders and standard ES cell media con-
taining 15% ES-qualified FBS (SH30070.03E; Hyclone). The inner 
cell mass (ICM) was allowed to grow out and was trypsinized after 
Our animal screening system is limited, because it relies on 
epistasis with Cd2ap and Synpo. Because of this, it is possible that 
on a different genetic background, Dlg5 might be an FSGS suscep-
tibility gene. If all susceptibility genes are components of a single 
network of genes involved in disease pathogenesis, a strategy 
such as ours could be very useful. Conversely, our strategy could 
be used to determine whether one or more networks of genes are 
involved by using ES cells with different genetic backgrounds.
Without knowing how many different networks of pathways 
are involved in FSGS, our animal screening strategy might not be 
sensitive to testing all susceptibility genes. While less of a prob-
lem in mice compared with zebrafish or Drosophila, differences 
between mice and humans in the expression of gene paralogs might 
be important. The differences we observed between Kank1 and 
Kank2 RNAi cohorts could be due to differences in their expression 
in murine versus human podocytes. Alternatively, it could be dif-
ferences in epistatic interactions between Cd2ap/Synpo and Kank1 
versus Kank2. As we showed with Kank1 RNAi mice, our system is 
potentially more sensitive if a longer screening period was used. As 
proteinuria and FSGS begin to be manifest in mice around 4 to 6 
months of age, we purposefully designed the screen to conclude 
after 8 weeks of RNAi expression.
Our method is similar in principle to one described by Prems-
rirut et al. that targeted shRNAs to the Col1a1 locus using ES cells 
developed by Jaenisch and coworkers. These ES cells expressed 
the rtTA ubiquitously from the Rosa locus (58, 59). We originally 
tried this method and found that transgenes targeted to the Col1a1 
locus were weakly expressed in the podocyte (data not shown). In 
addition, our method used an ES cell line from a sensitized back-
ground, allowing us to customize our screen for FSGS. Our method 
is distinct from that of Premsrirut et al., who used tetraploid com-
plementation, which is much more labor intensive and produces 
far fewer transgenic animals (59). The ability to derive ES cells 
from various disease-susceptible backgrounds should make our 
approach suitable for a wide variety of disease models.
With the availability of large-scale DNA sequencing of human 
populations, the identification of disease candidate genes and 
potential disease-associated variants will become more com-
mon. How these candidate genes and variants will be validated is 
unclear. Here, we demonstrate a pipeline that uses common and 
rare variant association analyses to identify candidate genes from 
sporadically affected unrelated individuals and control sequence 
data that were previously generated. We then developed a method 
to allow these candidates to be tested in vivo. Our method relied 
on generating an ES cell line that was sensitized for the develop-
ment of FSGS. It should be possible to generate ES cells on other 
disease-specific backgrounds to allow for validation studies that 
will be required to facilitate the discovery of genetic variants asso-
ciated with both rare and common diseases.
Methods
Exon capture and Illumina sequencing. Sample preparation and 
sequencing were carried out using standard protocols for targeted cap-
ture and Illumina sequencing. In brief, genomic DNA was fragmented 
to 150 to 200 bp using a Covaris E220 Focused Ultrasonicator. The 
ends of the fragmented DNA were repaired using a mixture of T4 
DNA polymerase, Klenow polymerase, and T4 polynucleotide kinase. 
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Transmission electron microscopy. Portions of kidney cortex were 
fixed with 2% paraformaldehyde and 2% glutaraldehyde. Specimen 
processing, ultrathin sectioning, and imaging were performed by the 
Electron Microscopy (EM) Core Facility at Washington University.
Statistics. P values of all albumin/creatinine ratio plots (Figure 3, C 
and F, and Figure 4, B–G) were calculated using a 2-tailed Mann-Whit-
ney U test. For Figure 3, C and F, a P value of less than 0.05 was consid-
ered statistically significant. For Figures 4, B–G, a P value of less than 
0.0083 was considered statistically significant (the multitest penalty 
was applied). All error bars represent the mean ± SEM.
Study approval. All animal experiments were conducted with the 
approval of the Washington University Animal Studies Committee. 
Because all of the patient samples were deidentified, the Washington 
University IRB deemed these studies exempt from IRB approval.
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5 to 7 days, depending on the size and shape of the outgrowth. Cells 
were cultured until ES colonies were identified. The colonies were 
expanded and genotyped using standard methods.
Generation of miR30-shRNA knockin transgenic mice. Integration 
of a single-copy transgene into the Hprt1 locus using 6-thioguanine 
was performed as we previously described (45) and was modified by 
the addition of a puromycin resistance cassette to increase the effi-
ciency of selection of a positive ES clone. A PGK-Puro cassette was 
inserted between the left and right arm of the pHPRT targeting vec-
tor. The miR30-based shRNA-expressing transgene that was driven 
by the tetracycline-responsive promoter (TRE) was inserted between 
the left arm and the PGK-Puro cassette. The linearized targeting vector 
was transfected into ES cells. Twenty-fours hours after transfection, 
the ES cells were treated with 1 μg/ml puromycin for 48 hours. After 
passaging once, the ES cells were treated with 6-thioguanine (5 μg/ml) 
for an additional 48 hours. Surviving ES cell colonies were selected, 
expanded, and examined by genomic PCR across the right arm (for-
ward primer: 5′-CAAGCCCGGTGCCTGATCTAGATCATAATC-3′; 
reverse primer: 5′-CTGTAAAGGTCTCTGAACTACCAATTGCAC-3′). 
Positive ES cells were then stocked for injection.
Laser-assisted microinjection. The ES cells were maintained at the 
expansion phase before injection. Eight ES cells were injected into a 
recipient embryo at the 8-cell stage by following a protocol published 
previously (44). Since the ES cell line produces mice with agouti coat 
color, albino B6 (C57BL/6J-Tyrc–2J) mice were used as hosts to allow for 
direct evaluation of chimerism by coat color.
Cell culture and lentiviral infection. Immortalized murine podo-
cytes were maintained and differentiated as described previously 
(25). To examine the knockdown efficiency of CD2AP-sh877, podo-
cytes were infected with lentiviral vectors encoding miR30-sh877. A 
control lentiviral vector encoding miR30-FF3 that targets firefly luci-
ferase cDNA was used as a control. CD2AP expression was examined 
by immunoblot analysis of the whole-cell lysates.
Design and validation of the miR30-shRNA constructs for genes of 
interest. The shRNA oligo sequences were chosen using an online 
algorism (http://katahdin.cshl.org/siRNA/RNAi.cgi?type=shRNA) 
as described previously (48). The miR30-shRNA backbone was sub-
cloned by PCR from pPRIME-CMV-GFP-FF3 (https://www.addgene.
org/11663/) and inserted into a pcDNA3.1-Zeo(+) vector to generate 
the pcMIR vector. To examine knockdown efficiency, the miR30-
shRNA construct and its artificial target (Supplemental Figure 3B) were 
cotransfected into HEK293T cells at a molar ratio of 5:1. The expression 
of EGFP in whole-cell lysates was examined by immunoblot analysis.
Abs. The Abs used for immunoblotting were mouse anti-XFP 
(632381; 1:10,000 dilution; Clontech); rabbit anti-ERK2 (sc-154; 
1:5,000 dilution; Santa Cruz Biotechnology Inc.); mouse anti–β-actin 
(A2228; 1:10,000 dilution; Sigma-Aldrich); and rabbit anti-CD2AP 
(generated in our previous study; 1:10,000 dilution).
Albumin-creatinine assay. Mouse urine samples were collected at 
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